Immunotherapy + radiation show promise for bladder preservation in localized MIBC, phase II study shows

CAR T therapy shows durable responses in large B-cell lymphoma

Allogene Therapeutics Inc. announced the publication of data from its phase I ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory large B-cell lymphoma as a rapid communication in the Journal of Clinical Oncology.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Scientists identify dysfunctional B cells as a new cancer immunotherapy target

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood—known as the tertiary lymphoid structure—where they become dysfunctional when in close contact with tumors.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show

Interim analysis of a clinical trial led by Fox Chase Cancer Center researchers shows promise for the treatment of patients with muscle-invasive bladder cancer.

February 14, 2025

Vol.51 No.06

Clinical Roundup

Researchers identify gut bacteria as key to ovarian cancer immunotherapy resistance

University of Virginia Cancer Center researchers explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

February 14, 2025

Vol.51 No.06